Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider

In the latest close session, Viking Therapeutics, Inc. (VKTX) was up +1.07% at $36.01. The stock outpaced the S&P 500's daily gain of 1.01%. Elsewhere, the Dow saw an upswing of 0.83%, while the tech-heavy Nasdaq appreciated by 1.22%.

Shares of the company have appreciated by 22.86% over the course of the past month, outperforming the Medical sector's loss of 5.53%, and the S&P 500's loss of 2.86%.

Analysts and investors alike will be keeping a close eye on the performance of Viking Therapeutics, Inc. in its upcoming earnings disclosure. The company is forecasted to report an EPS of -$1.01, showcasing a 146.34% downward movement from the corresponding quarter of the prior year.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$4.15 per share and a revenue of $0 million, representing changes of -30.09% and 0%, respectively, from the prior year.

Investors should also note any recent changes to analyst estimates for Viking Therapeutics, Inc. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 4.06% higher. Currently, Viking Therapeutics, Inc. is carrying a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 143, placing it within the bottom 42% of over 250 industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow VKTX in the coming trading sessions, be sure to utilize Zacks.com.

Zacks' Research Chief Picks Stock Most Likely to "At Least Double"

Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.

See Our Top Stock to Double (Plus 4 Runners Up) >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Viking Therapeutics, Inc. (VKTX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research